Skip to main content
. 2021 Jun 9;22(12):6234. doi: 10.3390/ijms22126234

Figure 5.

Figure 5

Changes in plasma exosomes (shown as total sEV protein level) of HNSCC patients treated with cetuximab/IMRT/ipilimumab. Five patients had recurrence and 13 were NED at 2 yrs. after therapy. Note decreased exosome protein in patients who remained NED for >2 yrs. * p = 0.05; ** p = 0.005. ND= normal donors. Reproduced from ref [80].